Tischler's early research helped establish that pheochromocytoma cells could undergo neuron-like differentiation in response to nerve growth factor (NGF).[5]
In 1976, he and Lloyd Greene[6] co-developed the widely used PC12cell line.[7]
Tischler served as President of the Endocrine Pathology Society (2001–2002)[10] and was Editor-in-Chief of Endocrine Pathology (2002–2008).[11] He is also a founding member of the Pheochromocytoma Research Support Organization (PRESSOR), where he co-chaired the tumor models working group.
Tischler contributed to the Cancer Genome Atlas (TCGA) pheochromocytoma/ paraganglioma study,[18] and is a collaborator in the Australian-Asian-American Adrenal Alliance (A5)[19].[20]
Selected publications
Tischler AS, Greene LA. "Nerve growth factor-induced process formation by cultured rat pheochromocytoma cells." Nature. 1975.[21]
Greene LA, Tischler AS. "Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells..." PNAS. 1976.[22]
Powers JF, et al. "A xenograft and cell line model of SDH-deficient pheochromocytoma..." Endocrine-Related Cancer. 2020.[23]
↑ DeLellis, Ronald A., ed. (2004). Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours. Lyon: IARC Press. ISBN978-92-832-2416-7.
↑ WHO classification of tumours: endocrine and neuroendocrine tumours (5thed.). Lyon: International Agency for Research on Cancer, WHO. 2025. ISBN978-92-832-4524-7.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.